Compare SHMD & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | NBP |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | Germany | United States |
| Employees | N/A | 32 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 379.3M |
| IPO Year | N/A | N/A |
| Metric | SHMD | NBP |
|---|---|---|
| Price | $6.32 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 780.1K | 620.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $2.93 |
| 52 Week High | $10.65 | $5.19 |
| Indicator | SHMD | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 36.13 |
| Support Level | $2.38 | N/A |
| Resistance Level | $6.70 | $3.90 |
| Average True Range (ATR) | 0.98 | 0.30 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 14.78 | 3.33 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.